NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors in Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”) securities that a securities class action has been filed on behalf of all investors who purchased shares between August 6, 2024 and August 4, 2025 (the “Class Period”). Investors have until January 5, 2026 to seek appointment as lead plaintiff. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Allegations The complaint filed allege ...

WHEAT RIDGE, CO / ACCESS Newswire / November 12, 2025 / Lifeloc Technologies, Inc. (OTC:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended September 30, 2025. Third Quarter Financial Highlights Lifeloc posted quarterly net revenue of $2.257 million in the third quarter of 2025, resulting in a quarterly net loss of $(263) thousand, or $(0.10) per diluted share. ...

Core Insights - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. regarding alleged violations of federal securities laws related to misleading statements about the Inspire V device launch [3][6] - Investors who suffered losses from August 6, 2024, to August 4, 2025, are encouraged to contact the firm to discuss their legal options before the January 5, 2026, deadline for seeking lead plaintiff status in a federal securities class action [2][3] Company Performance - Inspire Medical announced significant setbacks in the launch of its Inspire V device on August 4, 2025, citing delays due to incomplete training and onboarding at treatment centers [7] - The company faced billing and reimbursement challenges, with necessary software updates for claims processing not effective until July 1, 2025, leading to continued use of the older Inspire IV system [7] - Demand for the Inspire V device was reported as weak, resulting in excess inventory and a drastic cut in 2025 earnings guidance by over 80% [8] Market Impact - Following the announcement of these issues, Inspire Medical's stock price plummeted by more than 32%, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025, erasing approximately $1.2 billion in market capitalization [8]

Financial Performance - KORU Medical Systems achieved record Q3 revenues of $10.4 million, a 27% increase compared to the prior year period, driven by the Core SCIg business[6, 20] - The company reported a net loss of $0.8 million but achieved a positive adjusted EBITDA of $0.09 million and generated $0.4 million in cash during Q3[6] - KORU Medical Systems is raising its 2025 revenue guidance to $40.5-$41.0 million, representing a growth of 20%-22%, and reiterating a gross margin of 61%-63%[6] Market and Growth Opportunities - The US SCIg market is forecasted to grow at 9%+ through 2029[8] - KORU Medical Systems has grown its international market share from approximately 10% to approximately 15-20% since 2024, with significant room for further penetration in the ~$60 million global SCIg market[11] Pipeline and Outlook - KORU Medical Systems has 7 collaborations/opportunities with Ig manufacturers, targeting a $450 million Total Ig TAM (Total Addressable Market)[12] - The company plans for 4 new drug additions on the KORU Freedom Infusion System by 2026, expanding internationally and pursuing drug labels independently, targeting a $1.8 billion Total TAM[13] - KORU Medical Systems is progressing with its strategic oncology infusion market entry initiative, with an anticipated market entry in 4Q25/1Q26, targeting a ~$138 million 2025 TAM[18, 19]

San Diego, California--(Newsfile Corp. - November 12, 2025) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Inspire Medical Systems, Inc. (NYSE: INSP) common stock between August 6, 2024 and August 4, 2025, both dates inclusive (the "Class Period"), have until January 5, 2026 to seek appointment as lead plaintiff of the Inspire Medical class action lawsuit. Captioned City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., No. 25-cv-0 ...

Core Insights - Solana Company (NASDAQ: HSDT) is set to release its third quarter operating results on November 18, 2025, after market close [1] - The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results and provide a business update [1] Company Overview - Solana Company is a leading neurotech firm focused on neurologic deficits, utilizing an orally applied technology platform to enhance the brain's compensatory mechanisms and promote neuroplasticity [2] - The company also operates a digital asset treasury dedicated to acquiring and holding Solana (SOL), aiming to maximize SOL per share through strategic capital market use and on-chain opportunities [2]

Core Viewpoint - LeMaitre Vascular, Inc. is actively engaging with investors through participation in three upcoming healthcare conferences, highlighting its commitment to investor relations and market presence [1]. Company Participation in Conferences - LeMaitre Vascular will present at the following investor conferences: - Jefferies London Healthcare Conference on November 18, 2025, with CFO Dorian LeBlanc presenting at 8:00 AM GMT [2]. - Wolfe Research 7th Annual Healthcare Conference on November 19, 2025, with President David Roberts presenting at 10:40 AM ET [2]. - Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, with CFO Dorian LeBlanc presenting at 3:20 PM ET [2]. Company Overview - LeMaitre Vascular specializes in devices, implants, and services for treating peripheral vascular disease, which affects over 200 million people globally [2]. - The company develops, manufactures, and markets both disposable and implantable vascular devices tailored for vascular surgeons [2].

Core Insights - LogicMark, Inc. reported an 8% year-over-year revenue increase for Q3 2025, reaching $2.9 million, driven by strong sales of its Freedom Alert Mini units and the upgraded Guardian Alert 911 Plus [6][11] - The company maintained a gross margin of 66%, consistent with previous periods, indicating stable profitability despite increased operating expenses [7][11] - LogicMark's net loss for the quarter was $1.7 million, slightly higher than the previous year, with a loss per share of $2.21, reflecting a reverse stock split completed in October 2025 [9][21] Financial Performance - Revenue for Q3 2025 was $2.9 million, up from $2.7 million in Q3 2024, marking a consistent growth trend over five of the last six quarters [6][11] - Gross profit increased to $1.9 million from $1.8 million year-over-year, maintaining a strong gross margin of 66% [7][11] - Total operating expenses rose to $3.7 million from $3.4 million in the same quarter last year, attributed to hiring additional sales personnel [8][11] Operational Highlights - The company has integrated new features such as Medication Reminders and Proactive Activity Metrics into its products, enhancing its AI strategy for proactive health monitoring [4][11] - LogicMark's focus on business-to-business channels and reseller momentum has contributed to its sales growth [3][11] - The company reported cash and investments totaling $11.7 million with no long-term debt as of September 30, 2025, indicating a solid financial position [10][11] Strategic Direction - LogicMark's product roadmap is guided by principles of safety, simplicity, and real-time visibility, particularly for seniors and caregivers [5][11] - The company is committed to serving U.S. veterans through its VA channels, reinforcing its dedication to this demographic [5][11]

Core Insights - Pulmonx Corporation reported a total worldwide revenue of $21.5 million for Q3 2025, reflecting a 5% increase from $20.4 million in Q3 2024, and a 4% increase on a constant currency basis [4][9] - The company aims to leverage its operational foundation to expand Zephyr Valve treatment volumes while maintaining a commitment to sustainable, profitable growth [3][4] Financial Performance - U.S. revenue for Q3 2025 was $14.0 million, a 1% increase year-over-year, while international revenue reached $7.5 million, marking a 15% increase compared to Q3 2024 [4][9] - Gross profit for Q3 2025 was $16.1 million, with a gross margin of 75%, up from 74% in the same period last year [5][9] - Operating expenses increased by 4% to $30.4 million, driven by higher clinical, development, and commercial investments [5][9] - The net loss for Q3 2025 was $14.0 million, or $0.34 per share, slightly improved from a net loss of $14.1 million, or $0.36 per share, in Q3 2024 [6][9] 2025 Financial Outlook - Pulmonx updated its 2025 financial outlook, expecting total revenue to be in the range of $89 million to $90 million, with a gross margin of approximately 73% [7][9] - Total operating expenses for the full year 2025 are projected to be between $125 million and $126 million, including about $21 million in non-cash stock-based compensation [7][9] Leadership Changes - Glen French was reappointed as President and CEO, and Derrick Sung was appointed as COO and CFO [9]

Electromed, Inc. Investor Presentation November 12, 2025 NYSE American: ELMD Innovation Leader in Airway Clearance Technologies Investor Presentation | 2 Electromed – Who We Are Electromed, Inc. is a growing medical device company focused on airway management to help people around the world breathe better, stay healthier, and lead active and fulfilling lives. *As of and for 12 months ended 9/30/2025 Key Stats: Headquarters: New Prague, MN Ticker: ELMD Established: 1992 Annual Revenue: $66.2M* Market Cap: $2 ...